IFx-2.0 received orphan drug designation for cutaneous melanoma, offering benefits like market exclusivity and tax credits. Phase 1 study data showed IFx-2.0 benefits patients resistant to anti-PD1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results